Narasimhan Mani - 19 Sep 2024 Form 4 Insider Report for Scienture Holdings, Inc. (SCNX)

Reporting relationship: President & Co-CEO, Director
Issuer ticker: SCNX
Reported as of: 19 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Mar 2026, 21:32:38 UTC
Prior SEC filing: 05 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani

Key filing fact

Narasimhan Mani filed Form 4 for Scienture Holdings, Inc. (SCNX) on 12 Mar 2026.

Key facts

This page summarizes Narasimhan Mani's Form 4 filing for Scienture Holdings, Inc. (SCNX).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Mar 2026, 21:32.

Change

Previous filing in this sequence was filed on 05 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002031317 Primary reporting owner

Narasimhan Mani

Relationship: President & Co-CEO, Director
Address: C/O SCIENTURE HOLDINGS, INC., 20 AUSTIN BLVD., COMMACK
Signature: /s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani
Signature date: 12 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCNX transaction

Common Stock, par value $0.00001

Conversion of derivative security

Transaction value
Shares: +1,357,538
Change %: +2342%
Price
Shares after: 1,415,515
Date: 19 Sep 2024
Ownership: By Srivatsav, LLC
Footnotes: F1, F2

SCNX transaction

Common Stock, par value $0.00001

Other

Transaction value
Shares: -20,000
Change %: -1.4%
Price: $0.000000^*
Shares after: 1,395,515
Date: 10 Mar 2025
Ownership: By Srivatsav, LLC
Footnotes: F2, F3

SCNX transaction

Common Stock, par value $0.00001

Award

Transaction value
Shares: +750,000
Change %
Price: $0.000000^*
Shares after: 750,000
Date: 14 Apr 2025
Ownership: Direct
Footnotes: F4

SCNX transaction

Common Stock, par value $0.00001

Award

Transaction value
Shares: +300,000
Change %: +40%
Price: $0.000000^*
Shares after: 1,050,000
Date: 01 Oct 2025
Ownership: Direct
Footnotes: F5

SCNX transaction

Common Stock, par value $0.00001

Award

Transaction value
Shares: +500,000
Change %: +48%
Price: $0.000000^*
Shares after: 1,550,000
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCNX transaction Derivative

Series X Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,357,538
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Sep 2024
Ownership: By Srivatsav, LLC
Underlying class: Common Stock, par value $0.00001
Underlying amount: 1,357,538
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.

Footnote F2

These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Footnote F3

These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto.

Footnote F4

These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.

Footnote F5

These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.

Footnote F6

On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.